Taken together, our results demonstrate that perturbation of the interaction between Rab22a-NeoF1 and PYK2 using the 1–10 a.a.-iRGD peptide abrogates the promotion of its negative recipient cancer cells metastasizing to lungs induced by Rab22a-NeoF1 fusion protein. Here, RAB22A is linked to cancer.